Karyopharm Therapeutics
178 articles with Karyopharm Therapeutics
-
XPOVIO™ (selinexor) Now Available to Excelera Network Members for Treatment of Relapsed or Refectory Multiple Myeloma
10/8/2019
As part of the innovative treatments offered through the Excelera Network, members granted immediate access to XPOVIO upon the treatment's accelerated FDA approval in July 2019
-
AmerisourceBergen Selected by Karyopharm to Support XPOVIO™
10/1/2019
New rare disease therapy supported by AmerisourceBergen’s unified offerings including specialty pharmacy dispensing, distribution services, 3PL and community oncology services
-
DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors That a Class Action Lawsuit Has Been Filed Against Karyopharm Therapeutics, Inc. (NASDAQ: KPTI) and Encourages Karyopharm Investors to Contact the Firm
9/19/2019
Bragar Eagel & Squire, P.C. reminds investors that a class action lawsuit has been filed in the United States District Court for the District of Massachusetts on behalf of all investors that purchased Karyopharm, Inc. securities between March 2, 2017 to February 22, 2019.
-
KPTI INVESTOR ALERT: Hagens Berman Alerts Investors in Karyopharm Therapeutics (KPTI) Public Offerings to Possible Disclosure Violations
7/25/2019
Hagens Berman Sobol Shapiro LLP alerts investors in Karyopharm Therapeutics Inc.'s April 28, 2017 and May 7, 2018 public offerings to the firm's investigation into possible securities law violations.
-
KPTI CLASS ACTION ALERT: Bernstein Liebhard LLP Announces That a Securities Class Action Lawsuit has Been Filed Against Karyopharm Therapeutics Inc.
7/24/2019
Bernstein Liebhard LLP announces that a securities class action lawsuit has been filed on behalf of those who purchased or acquired the securities of Karyopharm Therapeutics Inc. ("Karyopharm" or the "Company") (NASDAQ: KPTI) from March 2, 2017, through February 22, 2019 (the "Class Period").
-
Bernstein Litowitz Berger & Grossmann LLP Announces Securities Class Action Suit Filed Against Karyopharm Therapeutics Inc. And Certain Of Its Senior Exec, Its Board Of Directors, And Underwriters Of Its Ap 2017 And May 2018 Stock Offerings
7/23/2019
Bernstein Litowitz Berger & Grossmann LLP announced that it filed a securities class action lawsuit on behalf of its client Allegheny County Employees' Retirement System against Karyopharm Therapeutics Inc., and certain of the Company's senior executives, Karyopharm's Board of Directors, and the underwriters of the Offerings,.
-
XPOVIO™ (selinexor) Available for Order at Biologics by McKesson
7/8/2019
Biologics by McKesson, an independent specialty pharmacy for oncology and other complex therapeutic areas, announced that it has been selected by Karyopharm Therapeutics, Inc. to be in the limited distribution network for XPOVIO™ (selinexor).
-
Shares of Karyopharm Therapeutics have skyrocketed more than 36% after the U.S. Food and Drug Administration approved the Newton, Mass.-based company’s treatment for multiple myeloma.
-
The month of July is a slow one for the U.S. Food and Drug Administration (FDA), at least in terms of scheduled approval dates. Here’s a look at the three PDUFA dates the agency has on its calendar for the month.
-
Karyopharm Announces FDA Extension of Review Period for Selinexor New Drug Application
3/14/2019
Karyopharm Therapeutics Inc. announced that the U.S. Food and Drug Administration (FDA) has extended the Prescription Drug User Fee Act (PDUFA) action date for the New Drug Application (NDA) for selinexor.
-
FDA Advisory Panel Recommends Waiting for More Data Before Approving Karyopharm’s Selinexor
2/27/2019
Shares of Karyopharm Therapeutics are crashing again after an advisory panel from the U.S. Food and Drug Administration recommended delaying potential approval of the company’s experimental multiple myeloma treatment until additional data is available from an ongoing Phase III study. -
Karyopharm Plunges After FDA Briefing Materials Raise Questions About Safety of Multiple Myeloma ...
2/25/2019
The FDA noted some concerns over the drug’s safety profile. Treatment with selinexor is associated with significant toxicity, the agency noted in its materials. -
Karyopharm’s Selinexor Receives Fast Track Designation from FDA for the Treatment of Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma
11/7/2018
Karyopharm Therapeutics Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to selinexor, the Company’s first in class, oral SINE compound, for the treatment of patients with diffuse large B-cell lymphoma (DLBCL) who have received at least two prior therapies and are not eligible for high dose chemotherapy with stem cell rescue or CAR-T therapy.
-
Researchers at the University of California, San Diego (UCSD) ran successful animal studies of a gene therapy that appeared to cure a disease in mice similar to amyotrophic lateral sclerosis (ALS), sometimes also known as Lou Gehrig’s Disease.
-
Karyopharm Announces Results of Clinical Studies Investigating Selinexor in Multiple Myeloma and Diffuse Large B-Cell Lymphoma to be Presented at the American Society of Hematology 2018 Annual Meeting
11/1/2018
Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that ten abstracts have been selected for presentation, including three oral presentations, at the upcoming American Society of Hematology (ASH) 2018 Annual Meeting being held December 1-4, 2018 in San Diego.
-
U.S. Food and Drug Administration Accepts Karyopharm’s New Drug Application for Selinexor and Grants Priority Review
10/5/2018
Application Seeks Accelerated Approval for Selinexor as a Treatment for Patients with Penta-Refractory Multiple Myeloma
-
Karyopharm to Present Phase 2b STORM Data Evaluating Selinexor in Patients with Penta-Refractory Multiple Myeloma at the Society of Hematologic Oncology 2018 Annual Meeting
8/28/2018
Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that clinical data from the Phase 2b STORM study evaluating the Company’s lead, oral Selective Inhibitor of Nuclear Export (SINE) compound selinexor in heavily pretreated patients with refractory multiple myeloma, has been selected for oral presentation at the Society of Hematologic Oncology (SOHO) 2018 Annual Meeting.
-
Within the next six years, the multiple myeloma market is projected to be $37.5 billion – an incredible growth of $30 billion since 2015, when the market was valued at about $7.5 billion.
-
Just about every week has plenty of exciting news in the biopharmaceutical industry, and this week was no different. Here’s a brief look back at some of our top stories.
-
With Strong Data Karyopharm Intends to Seek FDA Approval for Multiple Myeloma Drug Selinexor
5/1/2018
Shares of Newton, Mass.-based Karyopharm Therapeutics is skyrocketing in premarket trading after the company announced late Monday it will seek U.S. Food and Drug Administration approval for its investigational drug selinexor following strong top-line results from a Phase IIb trial.